PrEP.

Slides:



Advertisements
Similar presentations
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Advertisements

STDs Valerie Robinson D.O.. Prevention Abstinence Risk reduction Vaccines Male or female condoms Cervical diaphragm might protect against cervical GC,
PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014.
Unmet need for family planning and low rates of dual method protection among men and women attending HIV care and treatment services in Kenya, Namibia.
Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.
Integration with ART for HIV+ Heterosexual men Risk of Resistance MSM High-risk women Young MSM of color Transgender women Long-term safety Provider attitudes.
UN Cares PEP Starter Kit Custodians Training MODULE 4: HIV Post-Exposure Prophylaxis Starter Kits.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Michael Hughes, MD Assistant Clinical Professor UCR Eisenhower Medical Associates.
2007 Youth Risk Behavior Survey Results Alaska High School Survey Grades 9-12 Alaska Division of Public Health Weighted Data Sexual Behaviors.
Pharmacist-Managed HIV Pre-Exposure Prophylaxis (PrEP) Clinic: Preliminary Outcomes From an Urban Community Health Clinic Mark T. Sawkin, PharmD, AAHIVP.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
Dual Protection = prevent pregnancy + avoid STI/HIV.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
PrEP Facts Clinical trials have shown daily oral Tenofovir to effectively prevent HIV acquisition PrEP must only be prescribed for HIV- patients and patients.
Understanding the Rationale of the 2015 WHO Guidelines on PrEP IAS Satellite Session Heather Watts M.D. Office of the Global AIDS Coordinator July 18,
Providing PrEP – The Basics
Information about HIV Prevention Options
PrEP for HIV Prevention
A protocol in development IMPAACT Prevention Scientific Committee
2017 Key Considerations for adolescents and children & Key populations
On behalf of The MTN-020/ASPIRE Study Team
Module 4 (a) Getting started on PrEP
Quarraisha Abdool Karim, PhD
PrEP: A Case-by-Case Approach
HIV and the ART of Prevention
Optimizing Statin Therapy
National Department of Health: South Africa
Risk of Treatment Failure: Patient Support approaches and strategies
Managing Women Living With HIV Infection
PrEP and Key populations: WHO guidelines & recommendations
Overview.
Infection Prevention: A Hierarchy of Controls Approach
Expert Perspectives on Clinically Challenging Cases in Narcolepsy
PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.
Tearing Down Fences HIV/STD Prevention in Rural America
RSV Bronchiolitis.
HPV-Related Disease: Separating Fact From Fiction
Statin Selection in Special Patient Populations: A Case Challenge
Before and After: Patient Cases in Onychomycosis
PrEP in Women: Unique Considerations and Strategies
Surveying the Safety of NOACs in the Real World
HCV Screening.
Blood pressure control: dependence on adherence
Evaluation of the Patient With HCV Infection
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
Agenda. Agenda HIV in the United States HIV in the United States (cont)
Is it Time for a Paradigm Change in HIV Management?
National Department of Health: South Africa
Personalizing Statin Therapy in Patients With HIV
Initiating Pre-exposure Prophylaxis The PrEP Checklist
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
An Update from CROI and the Changing Landscape of HIV in NZ
From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP
Statins and HIV:.
100 Partners PrEP[5] Efficacy 75% Adherence 81% 80
PrEP Ongoing Care.
Revisiting the Pharmacoeconomics of HF
New Strategies to Reduce HF Readmissions
Considerations in Managing Seizures in Women
Secondary Prevention.
Clinical Challenges and Updates in Managing Seizure Clusters
Strategies for Infection Control in Cystic Fibrosis
HIV.
U=U Guidance for Implementation in Clinical Settings
Bob Holtkamp, Director of Prevention & Outreach
Presentation transcript:

PrEP

What Is PrEP?

PrEP Is Not ART

PrEP is Effective: Adherence Is Critical

Who Is at Risk for Acquiring HIV Infection?

Clinical Eligibility For PrEP

Summary of Guidance for PrEP Use

Follow-Up After Initiation of PrEP

Behavioral Risk Reduction Counseling

PrEP in Women

PrEP Is Not Just for MSM

Determining Who Is at Substantial Risk for HIV Infection

Daily Adherence Is More Important in Women

Safety of PrEP During Pregnancy and Breastfeeding

PrEP: Part of the HIV Prevention Strategy

Common Patient Questions About PrEP

Common Patient Questions About PrEP (cont)

PrEP + Condoms = Better Protection Against HIV

Abbreviations

References

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.